CompletedPhase 3

Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children

Germany207 participantsStarted 2008-02

Plain-language summary

Evaluation of safety and efficacy of sublingual immunotherapy with grass pollen allergens formulated as solution in comparison to a symptomatic standard treatment with add on placebo in grass pollen allergic children suffering from allergic rhinitis/rhinoconjunctivitis with or without bronchial asthma.

Who can participate

Age range4 Years – 11 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 4 - \<12 years (at the time of inclusion) * Positive SPT * Positive EAST * Positive CPT Exclusion Criteria: * Serious chronic diseases * Other perennial allergies

What they're measuring

Changes of Symptom-Medication-Score

Timeframe: After 1 year of treatment

Trial details

NCT IDNCT00841256

SponsorAllergopharma GmbH & Co. KG

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2012-06

View on ClinicalTrials.gov More Allergic Rhinoconjunctivitis trials